L-BLP25 vaccine plus letrozole induces a T H1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice

Clinical Cancer Research

Volumn 18, Issue 10, 2012, Pages 2861-2871

  Mehta, Neelima R ^a,b   Wurz, Gregory T ^a   Burich, Rebekah A ^a   Greenberg, Brittany E ^a   Griffey, Stephen ^c   Gutierrez, Audrey ^a   Bell, Katie E ^b   McCall, Jamie L ^a   Wolf, Michael ^d   DeGregorio, Michael ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Merck Serono GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; EMEPEPIMUT S; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LETROZOLE; MUCIN 1; TAMOXIFEN CITRATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TH1 CELL; TH1 TH2 BALANCE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; CANCER VACCINES; CYCLOPHOSPHAMIDE; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-12; MAMMARY NEOPLASMS, ANIMAL; MEMBRANE GLYCOPROTEINS; MICE; MUCIN-1; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; RANDOM ALLOCATION; TAMOXIFEN; TH1 CELLS; TRIAZOLES;

EID: 84861128128     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0168     Document Type: Article

References (44)

1. Lacey JV Jr, Devesa SS, Brinton LA. Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 2002;39:82-8. (Pubitemid 34260479) (Pubitemid 34260479)
2. Senn HJ, Morant R. Chemoprevention of breast and prostate cancers: where do we stand? Ann Oncol 2008;19 Suppl 7:vii234-7.
3. Al Masri A, Gendler SJ. Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis. Oncogene 2005;24:5799-808. (Pubitemid 43080071)
4. Takahashi T, Makiguchi Y, Hinoda Y, Kakiuchi H, Nakagawa N, Imai K, et al. Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol 1994;153:2102-9. (Pubitemid 24256681) (Pubitemid 24256681)
5. Choi C, Witzens M, Bucur M, Feuerer M,Sommerfeldt N, Trojan A, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005;105: 2132-4. (Pubitemid 40731802) (Pubitemid 40731802)
6. Lakshminarayanan V, Thompson P, Wolfert MA, Buskas T, Bradley JM, Pathangey LB, et al. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 2012;109:261-6.
7. Gaidzik N, Kaiser A, Kowalczyk D, Westerlind U, Gerlitzki B, Sinn HP, et al. Synthetic antitumor vaccines containing muc1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues. Angew Chem Int Ed Engl. 2011 Sep 9. [Epub ahead of print].
8. Pinkhasov J, Alvarez ML, Rigano MM, Piensook K, Larios D, Pabst M, et al. Recombinant plant-expressed tumour-associated MUC1 peptide is immunogenic and capable of breaking tolerance in MUC1.Tg mice. Plant Biotechnol J 2011;9:991-1001.
9. Wilkinson BL, Day S, Malins LR, Apostolopoulos V, Payne RJ. Selfadjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. Angew Chem Int Ed Engl 2011;50:1635-9.
10. Finn OJ, Gantt KR, Lepisto AJ, Pejawar-Gaddy S, Xue J, Beatty PL. Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas. Immunol Res 2011;50:261-8.
11. Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex - unrestricted recognition of tumor-associated mucins by human cyto-toxic T-cells. Proc Natl Acad Sci U S A 1989;86:7159-63. (Pubitemid 19240884) (Pubitemid 19240884)
12. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ. Cytotoxic T-cells from ovarian malignant-tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993;151: 3693-703. (Pubitemid 23282681) (Pubitemid 23282681)
13. Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 2008;7: 963-75.
14. Mukherjee P, Ginardi AR, Tinder TL, Sterner CJ, Gendler SJ. MUC1-specific cytotoxic T lymphocytes eradicate tumors when adoptively transferred in vivo. Clin Cancer Res 2001;7:848s-55s. (Pubitemid 33600936) (Pubitemid 33600936)
15. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005;4:493-502. (Pubitemid 41297296) (Pubitemid 41297296)
16. Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol 1998;10:1907-16. (Pubitemid 28566053) (Pubitemid 28566053)
17. Guan HH, Budzynski W, Koganty RR, Krantz MJ, Reddish MA, Rogers JA, et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 1998;9:451-8. (Pubitemid 28338759) (Pubitemid 28338759)
18. Butts C, Maksymiuk A, Goss G, Soulieres D, Marshall E, Cormier Y, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol 2011;137:1337-42.
19. Babina M, Kirn F, Hoser D, Ernst D, Rohde W, Zuberbier T, et al. Tamoxifen counteracts the allergic immune response and improves allergen-induced dermatitis in mice. Clin Exp Allergy 2010;40: 1256-65.
20. Behjati S, Frank MH. The effects of tamoxifen on immunity. Curr Med Chem 2009;16:3076-80.
21. Chen HM, Tritton TR, Kenny N, Absher M, Chiu JF. Tamoxifen induces TGF-beta 1 activity and apoptosis of humanMCF-7 breast cancer cells in vitro. J Cell Biochem 1996;61:9-17. (Pubitemid 26134170) (Pubitemid 26134170)
22. Komi J, Lassila O. Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells. Blood 2000;95:2875-82. (Pubitemid 30235898) (Pubitemid 30235898)
23. Joffroy CM, Buck MB, Stope MB, Popp SL, Pfizenmaier K, Knabbe C. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res 2010;70:1314-22.
24. Wang JX, Zhang QY, Jin S, Feng MY, Kang XM, Zhao S, et al. Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis. Exp Gerontol 2009;44:398-405.
25. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54: 721-8. (Pubitemid 40977140) (Pubitemid 40977140)
26. Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, et al. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003;26:47-62. (Pubitemid 36056825) (Pubitemid 36056825)
27. Wiebe VJ, Osborne CK,McGuire WL, DeGregorio MW.Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol 1992;10:990-4.
28. Zarghi A, Foroutan SM, Shafaati A, Khoddam A. Quantification of carvedilol in human plasma by liquid chromatography using fluorescence detection: application in pharmacokinetic studies. J Pharm Biomed Anal 2007;44:250-3. (Pubitemid 46551580) (Pubitemid 46551580)
29. Marfil F, Pineau V, Sioufi A, Godbillon SJ. High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection. J Chromatogr B Biomed Appl 1996;683: 251-8. (Pubitemid 26319570) (Pubitemid 26319570)
30. Liu JY, Wu Y, Zhang XS, Yang JL, Li HL, Mao YQ, et al. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 2007;56:1597-604. (Pubitemid 47094389) (Pubitemid 47094389)
31. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982;155:1063-74. (Pubitemid 12142723) (Pubitemid 12142723)
32. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8. (Pubitemid 40446280) (Pubitemid 40446280)
33. Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998;47:1-12. (Pubitemid 28430525) (Pubitemid 28430525)
34. Kim R, Lafreniere R, Borkenhagen K, Bryant LD. Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2. Cancer Immunol Immunother 1989;30: 283-8. (Pubitemid 20002342) (Pubitemid 20002342)
35. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41. (Pubitemid 37328666) (Pubitemid 37328666)
36. Srinivasan R, Van Epps DE. Specific active immunotherapy of cancer: potential and perspectives. Rev Recent Clin Trials 2006;1:283-92.
37. Tabi Z, Man S. Challenges for cancer vaccine development. Adv Drug Deliv Rev 2006;58:902-15. (Pubitemid 44709261) (Pubitemid 44709261)
38. Sharma S, Srivastava MK, Harris-White M, Lee JM, Dubinett S. MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer. Expert Opin Biol Ther 2011;11:987-90.
39. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007;9:R6.
40. Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P, et al. Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006; 15:2482-8. (Pubitemid 46048309) (Pubitemid 46048309)
41. Agrawal B, Reddish MA, Krantz MJ, Longenecker BM. Does pregnancy immunize against breast-cancer. Cancer Res 1995;55: 2257-61.
42. Lambe M, Hsieh CC, Chan HW, Ekbom A, Trichopoulos D, Adami HO. Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res Treat 1996;38:305-11. (Pubitemid 26126665) (Pubitemid 26126665)
43. Tuma R. Mimicking pregnancy to reduce breast cancer risk. J Natl Cancer Inst 2010;102:517-8.
44. Lukanova A, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, et al. Circulating estrogens and progesterone during primiparous pregnancies and risk of maternal breast cancer. Int J Cancer 2012; 130:910-20.